ARD-2128

Size	Price	Stock	Quantity
25 mg	$699	In stock
250 mg	$1990	In stock

Size

Price

Stock

Quantity

25 mg

$699

In stock

250 mg

$1990

In stock

Purity

≥98%

Solubility

Soluble in DMSO

Appearance

Light Yellow to Green Yellow Solid

Storage

Store at -20°C

IUPACName

N-[3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]-4-[4-[[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidin-4-yl]methyl]piperazin-1-yl]benzamide

Synonyms

ARD2128; ARD 2128; N-[(1r,3r)-3-(3-chloro-4-cyanophenoxy)-2,2,4,4-tetramethylcyclobutyl]-4-[4-[[1-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperidin-4-yl]methyl]piperazin-1-yl]benzamide

Boiling Point

1000.4±65.0°C at 760 Torr

Density

1.39±0.1 g/cm3

InChI Key

BWDWHHAZFQBJQL-JABICJEXNA-N

InChI

InChI=1S/C45H50ClN7O6/c1-44(2)42(45(3,4)43(44)59-32-11-7-29(25-47)35(46)24-32)49-38(55)28-5-8-30(9-6-28)52-21-19-50(20-22-52)26-27-15-17-51(18-16-27)31-10-12-33-34(23-31)41(58)53(40(33)57)36-13-14-37(54)48-39(36)56/h5-12,23-24,27,36,42-43H,13-22,26H2,1-4H3,(H,49,55)(H,48,54,56)/t36?,42-,43-

Canonical SMILES

N#CC1=CC=C(OC2C(C)(C)C(NC(=O)C3=CC=C(C=C3)N4CCN(CC4)CC5CCN(C6=CC=C7C(=O)N(C(=O)C7=C6)C8C(=O)NC(=O)CC8)CC5)C2(C)C)C=C1Cl

1. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer

Lijie Zhao, Weiguo Xiang, Xin Han, Bo Wen, Shaomeng Wang, Donna McEachern, Yu Wang, Aleksas Matvekas, Duxin Sun, Bukeyan Miao, Hoda Metwally, Chong Qin, Lu Wang J Med Chem . 2021 Sep 9;64(17):12831-12854. doi: 10.1021/acs.jmedchem.1c00882.

Proteolysis targeting chimera (PROTAC) small-molecule degraders have emerged as a promising new type of therapeutic agents, but the design of PROTAC degraders with excellent oral pharmacokinetics is a major challenge. In this study, we present our strategies toward the discovery of highly potent PROTAC degraders of androgen receptor (AR) with excellent oral pharmacokinetics. Employing thalidomide to recruit cereblon/cullin 4A E3 ligase and through the rigidification of the linker, we discovered highly potent AR degraders with good oral pharmacokinetic properties in mice with ARD-2128 being the best compound. ARD-2128 achieves 67% oral bioavailability in mice, effectively reduces AR protein and suppresses AR-regulated genes in tumor tissues with oral administration, leading to the effective inhibition of tumor growth in mice without signs of toxicity. This study supports the development of an orally active PROTAC AR degrader for the treatment of prostate cancer and provides insights and guidance into the design of orally active PROTAC degraders.

HNMR

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂